Does Hypofractionated Radiotherapy Regimens Increase the Vulnerability to SARS- COV-2 by Influencing ACE-2 Activity?

Author(s): Ghofrane Salhi Cherkaoui*, Sara Taleb, Youness Kadil, Houda Filali

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 4 , 2021

Become EABM
Become Reviewer
Call for Editor


In the context of the novel Coronavirus pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the management of patients with cancer constitutes a real challenge. These patients are more likely to be immunocompromised due to the underlying malignancy or anticancer treatments. As a consequence, they are more at risk of contracting this virus and tend to show a higher rate of fatal cases. In order to reduce the risk of this pandemic among patients and health care professionals, oncologists are currently proposing hypofractionated radiotherapy regimens using higher doses per fraction, thus shortening treatment courses and saving treatment visits. Since higher doses of radiation may also increase the ACE/ACE2 activity, which has been identified as a key SARS-CoV-2 receptor, this paper raises the question of whether hypofractionated radiotherapy regimens further increase the infectivity of these already vulnerable patients.

Keywords: Irradiation, radiation exposure, radiotherapy, SARS CoV 2, coronavirus, angiotensin converting enzyme (ACE), ACE2.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 09 November, 2020
Page: [419 - 421]
Pages: 3
DOI: 10.2174/2666796701999201109213143

Article Metrics

PDF: 12